中信证券股份有限公司 关于 北京神州细胞生物技术集团股份公司 2025 年度向特定对象发行 A 股股票 发行过程和认购对象合规性的报告 保荐人（主承销商） （二）发行价格 广东省深圳市福田区中心三路8号卓越时代广场（二期）北座 本次发行的定价基准日为公司第三届董事会第二次会议决议公告日，发行价 格为 36.00 元/股，不低于定价基准日前 20 个交易日公司股票交易均价的 80%。 上述均价的计算公式为：定价基准日前 20 个交易日股票交易均价=定价基准日前 20 个交易日股票交易总额/定价基准日前 20 个交易日股票交易总量。 1 二零二六年三月 上海证券交易所： 北京神州细胞生物技术集团股份公司（以下简称"神州细胞""发行人"或 "公司"）2025 年度向特定对象发行 A 股股票（以下简称"本次发行"）已获 得中国证券监督管理委员会（以下简称"中国证监会"）证监许可〔2025〕2971 号文同意注册批复。 中信证券股份有限公司（以下简称"中信证券"或"保荐人（主承销商）"） 作为神州细胞本次发行的保荐人（主承销商），对发行人本次发行过程及认购对 象的合规性进行了核查，认为神州细胞本次发行过程及认购对象符合 ...

3月27日午后，创新药概念持续走高，舒泰神涨超14%，昭衍新药、康弘药业、双鹭药业等多股涨停，神州细胞、首药控股、 百济神州、信立泰等均大幅上涨。 | 名称 | 涨跌幅▽ | 现价 | | --- | --- | --- | | 基石药业-B | 18.55% | 8.180 | | 石药集团 | 12.13% | 9.150 | | 华领医药-B | 10.93% | 3.450 | | 科济药业-B | 9.25% | 17.480 | | 映恩生物-B | 9.22% | 279.600 | | 先声药业 | 8.77% | 12.160 | | 亚盛医药-B | 7.95% | 46.160 | | 三生制药 | 7.46% | 23.340 | | 复宏汉霖 | 7.12% | 70.700 | | 恒瑞医药 | 7.10% | 65.600 | 编辑 ｜ 钉钉 | 名称 | 现价 | 涨跌幅 · | | --- | --- | --- | | 舒泰神 | 26.52 | 14.66% | | 迪哲医药-U | 57.12 | 10.70% | | 百利天恒 | 282.11 | 10.63% | ...

股票简称：神州细胞 股票代码：688520 北京神州细胞生物技术集团股份公司 2025 年度向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年十二月 北京神州细胞生物技术集团股份公司 2025年度向特定对象发行A股股票募集说明书 声 明 本公司及全体董事、高级管理人员承诺募集说明书内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担 相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或意 见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证， 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价 ...

证券代码：688520 证券简称：神州细胞 公告编号： 2026-004 北京神州细胞生物技术集团股份公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于近日收到控股股东拉萨爱力克通知，获悉其所持有公司的部分股份被质押， 具体情况如下： | | | | | | | | | | 单位：股 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 出质 人 | 是否 为控 | 本次质押 | 是否 | 是否 | 质押起 | 质押到 | | 占其所持 | 占公司 总股本 | | | | 股股 东 | 股数 | 为限 售股 | 补充 质押 | 始日 | 期日 | 质权人 | 股份比例 | 比例 | 质押用途 | | 拉萨爱 力克 | 是 | 35,000,000 | 否 | 否 | 2026- 03-19 | 办理解 除质押 | 中国工商 银行股份 有限公司 | 12.90% | 7.86% | 为申请银 ...

Core Viewpoint - Shenzhou Cell (688520.SH) reported a significant decline in revenue and a shift to net loss for the fiscal year 2025, primarily due to ongoing healthcare cost control policies and increased commercialization expenses [1] Financial Performance - The company achieved total operating revenue of 1.56 billion yuan, a year-on-year decrease of 37.91% [1] - The net profit attributable to the parent company was -553.29 million yuan, with a net profit excluding non-recurring gains and losses of -536.39 million yuan, marking a transition from profit to loss compared to the previous year [1] Factors Influencing Performance - The decline in revenue was significantly impacted by the deepening of healthcare cost control policies, leading to multiple price reductions of the core product, Anjia [1] - To facilitate market access and channel development for newly approved products, the company increased its commercialization investment, resulting in higher sales expenses [1] - The company continued to advance parallel research across multiple pipelines, with several projects in late-stage clinical research, maintaining high R&D expenditures that affected current profits, leading to a loss in 2025 [1]

Group 1 - The core point of the article is that Shenzhou Cell reported a significant decline in its financial performance for the year 2025, with total operating revenue of 1560.15 million yuan, representing a year-on-year decrease of 37.91% [2] - The net profit attributable to the parent company was reported at -553.29 million yuan, indicating a loss for the period [2]

Financial Performance - Total revenue for 2025 was CNY 156,015.30 million, a decrease of 37.91% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was CNY -55,329.37 million, a significant decline from CNY 11,195.11 million in the previous year[3] - The equity attributable to shareholders of the parent company decreased by 0.95% to CNY 13,956.18 million[3] Assets and Investments - The company's total assets increased by 16.73% to CNY 383,328.43 million at the end of the reporting period[3] - R&D investments remained high as multiple projects are in late-stage clinical research, contributing to the shift from profit to loss in 2025[6] Revenue Decline Factors - The decline in revenue was primarily due to the deepening of medical insurance cost control policies and multiple price reductions of the core product Anjain®[6] - Sales expenses increased as the company intensified commercialization efforts for newly approved products[6] Non-Operating Income - Non-operating income showed significant fluctuations due to reduced donations and increased government subsidies[7] Cautionary Notes - The company warns that the financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[8] - Investors are advised to be cautious regarding investment risks associated with the reported financial data[8]

Core Viewpoint - Shenzhou Cell reported a significant decline in revenue and a net loss for the fiscal year 2025, primarily due to healthcare cost control, price reductions of core products, and increased commercialization and R&D investments [1] Financial Performance - Total operating revenue for 2025 was 156,015.30 million yuan, representing a year-on-year decrease of 37.91% [1] - The net profit attributable to the parent company was -55,329.37 million yuan, indicating a shift from profit to loss [1] - Total assets at the end of the reporting period were 383,328.43 million yuan, an increase of 16.73% compared to the beginning of the year [1] - Equity attributable to the parent company's owners was 13,956.18 million yuan, a decrease of 0.95% from the start of the year [1] Factors Influencing Performance - The performance decline was mainly driven by factors such as healthcare cost control measures, price reductions of key products, and increased investments in commercialization and research and development [1]

Core Viewpoint - Shenzhou Cell forecasts a net profit loss of 520 million to 580 million yuan for 2025, primarily due to significant revenue decline from its core product Anjiah, impacted by medical insurance cost control and price reductions [1] Financial Performance - The company anticipates a net profit loss of 503 million to 563 million yuan after excluding non-recurring items, with R&D investment projected between 830 million to 870 million yuan [1] - In the Q3 2025 report, revenue decreased by 32.27% year-on-year, with a net profit loss of 251 million yuan and a debt ratio of 101.46% [1] Recent Developments - During an institutional survey, Shenzhou Cell disclosed that several products (e.g., SCT1000, SCT650C, SCTB14) have entered or are planned to advance to Phase III clinical trials, with some potentially entering the registration research phase in 2026 [2] - The company plans to advance several new product IND applications this year and considers overseas business development as a medium to long-term strategy, although specific transactions remain uncertain [2] Stock Performance - Over the past seven trading days, Shenzhou Cell's stock price has declined by 1.55%, with a price range fluctuation of 4.98% [3] - The latest closing price is 39.38 yuan, with trading volume gradually decreasing and turnover rate maintained between 0.24% and 0.46% [3] - The stock has underperformed compared to the overall decline in the pharmaceutical and biotechnology sector [3]

Group 1 - The company, ShenZhou Cell, has a strong research and development capability and plans to advance several product applications for IND this year [2]